Cited 0 times in
A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.